Goldenwell Biotech, Inc. (GWLL)

Market Cap	19.80M
Revenue (ttm)	557.00
Net Income (ttm)	-124.76K
Shares Out	99.00M
EPS (ttm)	-0.00
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,500
Average Volume	4,959
Open	0.2000
Previous Close	0.2000
Day's Range	0.2000 - 0.2000
52-Week Range	0.0586 - 0.3275
Beta	2.43
RSI	n/a
Earnings Date	Apr 11, 2025

About Goldenwell Biotech

Goldenwell Biotech, Inc., focuses on nutraceutical and dietary supplements business in the United States. It is developing JI MAI—bovine cardiac vascular active peptide; Double Proline AG – 3D active collagen peptide; cartilage peptide, a type II collagen peptide; Se Plus tablets and sugar master tablets. The company was incorporated in 2019 and is based in Hudson, Ohio.

• Industry: Packaged Foods
• Sector: Consumer Staples
• Founded: 2019
• Country: United States
• Stock Exchange: OTCMKTS
• Ticker Symbol: GWLL

Financial Performance

In 2023, Goldenwell Biotech's revenue was $2,340, a decrease of -95.10% compared to the previous year's $47,800. Losses were -$116,895, -88.13% less than in 2022.